BioLight Life Sciences Ltd. (IL:BOLT)
TASE:BOLT
Want to see IL:BOLT full AI Analyst Report?
Top Page
Biolight
(TASE:BOLT)
Select Model
Select Model
Rating:43Neutral
Price Target:
258.00
▼(-30.53% Downside)
Action:ReiteratedDate:04/24/26
The score is driven primarily by weak financial performance (minimal/zero recent revenue, ongoing losses, and persistent cash burn), reinforced by bearish technical signals with the stock trading below key moving averages and negative MACD. Valuation is not supportive due to negative earnings and lack of dividend data, with low leverage as the main mitigating factor.
Positive Factors
Low leverage
Very low debt levels materially reduce refinancing and near-term solvency risk, a durable strength for a cash-burning biotech. With minimal leverage the company has structural flexibility to access financing or withstand R&D cycles without immediate debt-service pressure.
Negative Factors
Revenue collapse
Revenue declining to zero signals a pre-commercial or stalled commercialization trajectory; this is a fundamental weakness that limits internal funding capacity. Without predictable revenue, the business remains dependent on external capital to cover R&D and operating costs over months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt levels materially reduce refinancing and near-term solvency risk, a durable strength for a cash-burning biotech. With minimal leverage the company has structural flexibility to access financing or withstand R&D cycles without immediate debt-service pressure.
Read all positive factors
Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪21.67M
Dividend YieldN/A
Average Volume (3M)11.86K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-100.00%
EPS Growth-29.02%
CountryIL
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-67.20
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolight Business Overview & Revenue Model
Company Description
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of produ...
How the Company Makes Money
null...
Biolight Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 219.00K | 118.00K | 63.00K | 3.00K |
| Gross Profit | -544.00K | 219.00K | 118.00K | 63.00K | 3.00K |
| EBITDA | -14.66M | -7.75M | -10.60M | -8.03M | -1.31M |
| Net Income | -11.73M | -7.14M | -26.02M | -7.85M | 382.00K |
Balance Sheet | |||||
| Total Assets | 42.41M | 34.12M | 33.45M | 57.01M | 64.17M |
| Cash, Cash Equivalents and Short-Term Investments | 23.65M | 13.47M | 8.64M | 17.63M | 33.71M |
| Total Debt | 772.00K | 599.00K | 91.00K | 527.00K | 443.00K |
| Total Liabilities | 2.24M | 3.38M | 3.15M | 3.32M | 2.75M |
| Stockholders Equity | 34.40M | 26.88M | 29.78M | 53.17M | 60.70M |
Cash Flow | |||||
| Free Cash Flow | -10.86M | -11.02M | -10.99M | -9.64M | -10.65M |
| Operating Cash Flow | -10.85M | -10.99M | -9.58M | -9.54M | -10.03M |
| Investing Cash Flow | -16.17M | 7.55M | -1.95M | -10.55M | 13.48M |
| Financing Cash Flow | 21.37M | 7.98M | 3.25M | -485.00K | 915.00K |
Biolight Technical Analysis
Negative
371.40
Price Trends
317.24
Negative
340.74
Negative
411.41
Negative
Market Momentum
-17.47
Negative
35.33
Neutral
55.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 371.4 is above the 20-day moving average (MA) of 282.46, above the 50-day MA of 317.24, and below the 200-day MA of 411.41, indicating a bearish trend. The MACD of -17.47 indicates Negative momentum. The RSI at 35.33 is Neutral, neither overbought nor oversold. The STOCH value of 55.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.
Biolight Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ₪36.55M | -9.73 | ― | ― | -96.19% | 97.86% | |
43 Neutral | ₪21.67M | -1.78 | ― | ― | -100.00% | -29.02% | |
43 Neutral | ₪18.58M | -0.13 | ― | ― | ― | 41.15% | |
42 Neutral | ₪19.68M | -1.46 | ― | ― | ― | ― |
* Healthcare Sector Average
IL:BOLT
Biolight
238.70
-345.30
-59.13%
IL:XTLB
Xtl Bio
3.10
-1.60
-34.04%
IL:BLRX
Bioline Rx
1.40
-0.50
-26.32%
IL:CANF
Can Fite Bio
459.30
457.80
30520.00%
IL:PPBT
Purple Biotech
1.00
-3.50
-77.78%
IL:MTLF
Matricelf
281.70
-27.20
-8.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.